Medicare covers focused ultrasound for Parkinson’s disease in some circumstances, but coverage is not universal. Eligibility and reimbursement vary by region, by the specific brain target being treated, and by whether you have Original Medicare or a Medicare Advantage plan. The procedure gained FDA clearance for treating Parkinson’s tremor (targeting the thalamus) and later for treating motor complications like dyskinesia (targeting a different brain structure), but the insurance landscape has lagged behind the clinical evidence in ways that can be frustrating for patients trying to access it.
Why Coverage Varies So Much
The fragmented nature of Medicare coverage for focused ultrasound comes down to how the system handles newer procedures. The FDA has cleared MRI-guided focused ultrasound (MRgFUS) for specific Parkinson’s indications, but an FDA clearance does not automatically translate into Medicare coverage nationwide. Local Medicare Administrative Contractors, the regional entities that process claims, make independent coverage decisions. That means a patient in one state may receive full coverage for a procedure that a patient in a neighboring state cannot get reimbursed for at all. The Parkinson’s Foundation has noted directly that focused ultrasound is not universally covered by Medicare, that eligibility and region both factor into reimbursement, and that patients should contact the treatment center in their area for specifics about insurance coverage.1Parkinson’s Foundation. Ultrasound Treatment Helps with Parkinson’s Movement Symptoms
Medicare Advantage plans add another layer of complexity. These private plans must cover everything Original Medicare covers, but they can impose their own prior authorization requirements and preferred provider networks. Some Medicare Advantage plans have been quicker to cover focused ultrasound than others, and the hoops a patient has to jump through for approval can differ significantly between plans. If you are considering focused ultrasound, verifying coverage specifics with both your plan and the treatment center before scheduling is not just advisable, it is essential to avoid surprise bills that can run into the tens of thousands of dollars.
Which Brain Targets and Symptoms Are Treated
Focused ultrasound for Parkinson’s is not a single procedure. It targets different structures in the brain depending on which symptoms are most disabling, and the clinical evidence, FDA status, and insurance coverage differ for each target.
The first target to gain FDA clearance was the ventral intermediate nucleus (VIM) of the thalamus, treated for medication-resistant tremor. This procedure, called a thalamotomy, destroys a tiny area of tissue responsible for generating tremor signals. Long-term data out to five years show that the tremor benefit in the treated arm is durable, with significant improvement in tremor scores sustained throughout follow-up.2PubMed Central. Focused Ultrasound Thalamotomy in Tremor Dominant Parkinson’s Disease: Long-Term Results One study of thalamotomy patients found a mean tremor improvement of about 75%, with accuracy of targeting strongly predicting how well tremor responded.3Journal of Neurosurgery. Pretherapeutic functional connectivity of tractography-based targeting of the ventral intermediate nucleus for predicting tremor response in patients with Parkinson’s disease after thalamotomy with MRI-guided focused ultrasound
The second target, the globus pallidus internus (GPi), was cleared more recently for treating motor complications of Parkinson’s, particularly dyskinesia and “off” period motor impairment. An early feasibility study showed that focused ultrasound pallidotomy improved dyskinesia scores by about 59% at three months and maintained a 43% improvement at 12 months, while motor signs on the treated side improved by roughly 45%.4PubMed. MR-guided focused ultrasound pallidotomy for Parkinson’s disease: safety and feasibility A pivotal randomized trial confirmed these results: about 69% of patients in the active-treatment group met the response threshold, compared with 32% in the control group, and roughly three-quarters of initial responders maintained their benefit at 12 months.5New England Journal of Medicine. Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinson’s Disease
A third target, the subthalamic nucleus (STN), is under active investigation. Three-year follow-up data from a subthalamotomy study showed that motor scores on the treated side improved by about 52% and held steady over that period.6PubMed Central. Prospective Long-term Follow-up of Focused Ultrasound Unilateral Subthalamotomy for Parkinson Disease The STN target has the potential to address a broader range of motor symptoms than VIM thalamotomy, which mainly helps tremor. However, STN-targeted focused ultrasound does not yet carry the same regulatory track record as the VIM and GPi procedures, which matters for insurance coverage decisions.
How Focused Ultrasound Compares to Deep Brain Stimulation
The comparison with deep brain stimulation (DBS) is almost always on patients’ minds, because DBS has been the go-to surgical option for Parkinson’s for decades, and most insurers, including Medicare, already cover it. Understanding the differences helps explain some of the coverage dynamics.
In terms of tremor suppression, the two approaches appear to perform similarly. A systematic review and network meta-analysis found no significant difference in parkinsonian tremor suppression between focused ultrasound and DBS across multiple brain targets.7Journal of Neurology, Neurosurgery & Psychiatry. Comparison of efficacy of deep brain stimulation and focused ultrasound in parkinsonian tremor: a systematic review and network meta-analysis A separate meta-analysis comparing motor performance and quality of life found that STN-targeted focused ultrasound actually ranked highest among the compared techniques for improving motor scores, ahead of both STN-DBS and GPi-DBS.8Frontiers in Neurology. Ameliorating motor performance and quality of life in Parkinson’s disease: a comparison of deep brain stimulation and focused ultrasound surgery
Where the two diverge is in their fundamental nature. DBS is reversible and adjustable: electrodes are implanted in the brain and connected to a pulse generator, and the stimulation settings can be fine-tuned over time. Focused ultrasound is ablative, meaning it permanently destroys a small area of tissue. That irreversibility is both a selling point (no implanted hardware, no battery replacements, no infection risk from an implant) and a limitation (if the effect fades or targets were imprecise, you cannot undo the lesion).9PubMed Central. High-intensity focused ultrasound (HIFU) versus deep brain stimulation (DBS) for refractory tremor: team DBS Focused ultrasound also requires no incision, no general anesthesia, and no overnight hospital stay in many cases, which for older adults or those with other health conditions can be a significant advantage.
From a coverage standpoint, the established insurance infrastructure around DBS sometimes works against focused ultrasound. Payers are comfortable with DBS billing codes and evidence. Focused ultrasound, as a newer entrant, still faces the predictable lag between clinical evidence and broad payer acceptance.
Who Is a Good Candidate
Not every person with Parkinson’s is eligible for focused ultrasound. The procedure relies on MRI guidance and requires ultrasound waves to pass through the skull, so the physical characteristics of your skull matter. A measurement called the skull density ratio (SDR) has traditionally been used to screen candidates, with values below 0.4 considered a potential barrier. However, research has complicated that picture. One study found that patients with lower SDRs did require more energy during treatment, but their clinical outcomes were not significantly worse than those of patients with higher SDRs.10PubMed. The relevance of skull density ratio in selecting candidates for transcranial MR-guided focused ultrasound That said, very low SDR values can still make the procedure technically difficult or impossible.
Beyond skull characteristics, clinical selection criteria generally include:
- Medication resistance: Symptoms that no longer respond adequately to levodopa or other Parkinson’s medications, or side effects like dyskinesia that have become disabling.
- Tremor dominance: For VIM thalamotomy specifically, the best candidates are those whose most disabling symptom is tremor rather than rigidity or slowness.
- Cognitive function: Patients with significant cognitive impairment are generally excluded because of difficulty cooperating during the hours-long MRI-guided procedure and because of the higher risk of worsening cognitive symptoms.
- Unilateral symptoms: Because the procedure treats one side of the brain at a time (and bilateral procedures carry higher risk), patients with symptoms predominantly on one side tend to benefit most.
Side Effects and Safety
Focused ultrasound is not risk-free, though its safety profile is generally favorable compared with open surgical procedures. A systematic review and meta-analysis pooling data from randomized controlled trials of focused ultrasound in Parkinson’s found that dizziness was the most commonly reported side effect, occurring significantly more often in the treatment group than the control group. Gait disturbances and facial disturbances were also noted, though the differences between treatment and control groups for those effects did not reach statistical significance. No significant difference in life-threatening events was observed between groups.11PubMed. Safety of Focused Ultrasound Ablation in Parkinson’s Disease: A Meta-Analysis of Randomized Controlled Trials
A broader meta-analysis covering MRgFUS procedures (including both Parkinson’s and essential tremor patients) found that about a quarter of patients experienced side effects related to the MRI or the head frame used during the procedure, with headache and dizziness most common. These typically resolved on their own within a few days. The most frequently reported neurological side effects were sensory abnormalities, unsteadiness, and speech difficulties, which generally improved within three months and had minimal impact on daily life.12Frontiers in Neurology. Efficacy and safety of magnetic resonance-guided focused ultrasound for Parkinson’s disease: a systematic review and meta-analysis
The procedure itself involves lying still in an MRI scanner for several hours with a stereotactic frame attached to the head. Head pain during sonication (the actual delivery of ultrasound energy) is common but manageable. Patients are awake throughout, which allows the treatment team to check for neurological changes in real time and adjust the procedure accordingly.
The Challenge of Bilateral Treatment
Parkinson’s disease usually affects both sides of the body eventually, but focused ultrasound has historically been performed on only one side of the brain at a time. Treating both sides has been cautiously investigated, and the results underscore why this remains a tricky area.
A staged bilateral subthalamotomy study found that after treating the second side, motor scores in the off-medication state improved by about 53% at six months. However, some patients experienced temporary contralateral dyskinesia, and speech disturbances occurred in several cases, though most resolved within months. Levodopa doses could be dramatically reduced after bilateral treatment, which itself helped resolve the dyskinesia.13JAMA Neurology. Staged Bilateral MRI-Guided Focused Ultrasound Subthalamotomy for Parkinson Disease
A separate multicenter trial of bilateral pallidothalamic tractotomy painted a more cautious picture. While the unilateral procedure was clearly safe and effective, the bilateral procedure added only small additional motor gains while increasing the rate of persistent moderate or severe side effects, particularly in speech, gait, and balance.14PubMed. Safety and efficacy of staged, bilateral magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for motor complications of Parkinson’s disease: a prospective, multicentre, single-arm trial These findings are consistent with decades of experience with bilateral ablative procedures for movement disorders: destroying tissue on both sides of the brain carries cumulative risks that are qualitatively different from unilateral treatment.
For insurance coverage, this matters because some patients who have had a successful unilateral procedure want to treat the other side, and payer willingness to cover the second treatment may depend on evolving evidence about the risk-benefit balance. Patients considering bilateral treatment should expect rigorous screening and a frank conversation with their neurologist about the added risks.
What Happens in Practice When You Try to Get Coverage
If you have Original Medicare and are considering focused ultrasound, the practical steps generally look like this: your neurologist refers you to one of the treatment centers equipped with the Insightec Exablate system (the only FDA-cleared device for this purpose). The center’s financial team will then work with your regional Medicare contractor to determine whether your specific indication is covered. For VIM thalamotomy to treat medication-refractory tremor, coverage is more established. For GPi pallidotomy to treat dyskinesia, coverage is still expanding. For STN subthalamotomy, coverage is unlikely outside of a clinical trial setting at this point.
Prior authorization is typically required, meaning your medical records, medication history, and neurological evaluations need to be submitted for review before the procedure is approved. Denials happen, and appeals are possible. Patient advocacy organizations, including the Parkinson’s Foundation and the Focused Ultrasound Foundation, can sometimes help navigate the appeals process. Medicare Advantage plans follow their own internal criteria but are bound to cover what Original Medicare covers for a given region once a determination has been made.
Out-of-pocket costs even with Medicare coverage can still be significant because of deductibles and copays. The total cost of the procedure itself (before insurance) ranges roughly from $50,000 to over $100,000 depending on the facility, which means even a 20% copay is a substantial amount. Financial counseling from the treatment center is standard practice and worth pursuing early in the process.
Travel and Access Barriers
Another practical reality is that the number of centers offering MRI-guided focused ultrasound for Parkinson’s remains limited. Most are in larger metropolitan areas, and rural patients may face significant travel costs. Research into equitable access to advanced neurotechnologies has highlighted the financial burden of repeated travel for treatment and follow-up, including time off work for both patients and caregivers.15Canadian Journal of Neurological Sciences. Mapping the Landscape of Equitable Access to Advanced Neurotechnologies in Canada While that study focused on Canada, the same dynamics apply in the United States, where patients from rural areas may need to travel hundreds of miles to a treatment center.
Focused ultrasound does have one advantage here compared to DBS: because there is no implanted hardware, follow-up visits tend to be less frequent. DBS patients often need regular programming sessions, especially in the months after implantation, which can mean repeated long-distance trips. Focused ultrasound patients still need follow-up imaging and clinical assessments, but the visit schedule is generally lighter.
Beyond Symptom Control: Experimental Frontiers
The focused ultrasound technology used in Parkinson’s treatment has a second, very different application that is still in early clinical trials but could eventually change the treatment landscape. At lower energy levels than those used for ablation, focused ultrasound combined with intravenous microbubbles can temporarily open the blood-brain barrier, the tightly sealed network of blood vessels that normally prevents most drugs from reaching brain tissue.
A phase I clinical trial has demonstrated that this approach is safe and feasible in patients with Parkinson’s disease dementia, successfully opening the blood-brain barrier in targeted cortical regions and confirming that the barrier reseals afterward.16PubMed Central. Blood-brain barrier opening with focused ultrasound in Parkinson’s disease dementia A separate study went further, showing that focused ultrasound could facilitate the delivery of viral vectors (used in gene therapy) into specific brain regions in both primates and Parkinson’s patients, with PET imaging confirming that molecules entered brain tissue that they normally could not reach.17PubMed Central. BBB opening with focused ultrasound in nonhuman primates and Parkinson’s disease patients: Targeted AAV vector delivery and PET imaging
None of these blood-brain barrier applications are covered by Medicare. They remain purely experimental. But they represent the reason focused ultrasound research attracts so much attention beyond its current role as an ablation tool. If the technology can reliably deliver gene therapies, growth factors, or other neuroprotective agents directly to degenerating brain regions, it could shift Parkinson’s treatment from symptom management to something closer to disease modification. That prospect is still years away from clinical reality, and the insurance coverage question would need to be answered all over again for each new application. But for patients tracking the field, it is worth knowing that the same device used for tremor ablation today could eventually serve a fundamentally different therapeutic purpose.